Martine A. Rothblatt Sells 1,274 Shares of United Therapeutics Corporation (UTHR) Stock
United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,274 shares of the company’s stock in a transaction that occurred on Thursday, September 21st. The stock was sold at an average price of $116.07, for a total transaction of $147,873.18. Following the transaction, the chief executive officer now owns 2,343 shares of the company’s stock, valued at $271,952.01. The transaction was disclosed in a filing with the SEC, which is available through this link.
Shares of United Therapeutics Corporation (UTHR) opened at 114.60 on Friday. The company has a market capitalization of $4.98 billion, a price-to-earnings ratio of 13.29 and a beta of 1.52. United Therapeutics Corporation has a 1-year low of $110.90 and a 1-year high of $169.89. The stock has a 50 day moving average of $128.37 and a 200-day moving average of $129.08.
United Therapeutics Corporation (NASDAQ:UTHR) last issued its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the consensus estimate of $3.61 by ($4.86). United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The firm had revenue of $444.60 million during the quarter, compared to analysts’ expectations of $391.53 million. During the same period in the previous year, the firm earned $4.42 earnings per share. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. Analysts forecast that United Therapeutics Corporation will post $10.09 earnings per share for the current year.
WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/24/martine-a-rothblatt-sells-1274-shares-of-united-therapeutics-corporation-uthr-stock.html.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Focused Wealth Management Inc increased its stake in shares of United Therapeutics Corporation by 17.5% in the first quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock worth $127,000 after buying an additional 140 shares during the period. Eagle Global Advisors LLC purchased a new position in shares of United Therapeutics Corporation in the second quarter worth $206,000. Clarity Capital KCPS Ltd. purchased a new position in shares of United Therapeutics Corporation in the first quarter worth $230,000. TLP Group LLC purchased a new position in shares of United Therapeutics Corporation in the second quarter worth $246,000. Finally, HPM Partners LLC increased its stake in shares of United Therapeutics Corporation by 0.8% in the second quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after buying an additional 15 shares during the period.
A number of research firms recently issued reports on UTHR. Jefferies Group LLC reiterated a “sell” rating and set a $105.00 price objective on shares of United Therapeutics Corporation in a research report on Thursday, June 8th. BidaskClub cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. ValuEngine cut shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. UBS AG restated a “sell” rating and issued a $106.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Finally, Oppenheimer Holdings, Inc. restated a “buy” rating on shares of United Therapeutics Corporation in a research report on Friday, September 8th. Six investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $134.50.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.